Scotiabank raised the firm’s price target on Arcellx (ACLX) to $133 from $93 and keeps an Outperform rating on the shares. The firm has restored its high conviction that the iMMagine-1 trial results will support anito-cel approval following the departure of the recently installed head of FDA’s Center for Biologics Evaluation and Research, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACLX:
- Arcellx Advances Phase 3 Study for Multiple Myeloma Treatment
- Arcellx initiated with a Buy at Citi
- Arcellx Inc’s Anito-cel: A Promising Market Entrant with Superior Efficacy and Safety in Multiple Myeloma Treatment
- Arcellx Inc’s Strategic Partnership with Kite Enhances Anito-cel Therapy Launch and Market Position
- Arcellx Inc’s Anito Cel Therapy: A Promising Contender in Multiple Myeloma Treatment with Strong Market Potential